{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:22:41Z","timestamp":1787847761086,"version":"build-2784847793"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To compare efficacy, safety, and cost-effectiveness of sertaconazole (2%) and luliconazole (1%) cream in patients with dermatophytoses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>Sixty-four patients with tinea corporis and tinea cruris infections were enrolled in this single-center, randomized, open\u2013label, parallel study. Following inclusion and exclusion criteria, patients were randomly divided into two treatment groups and received either sertaconazole 2% cream applied topically twice daily for 4 weeks and luliconazole 1% cream once daily for 2 weeks. At follow-up, efficacy was assessed clinically using 4-point physician global assessment (PGA) scale, composite score, and mycologically by KOH mount. Safety was assessed by monitoring adverse drug events at each visit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The primary efficacy variables including changes in pruritus, erythema, vesicle, and desquamation (4-point PGA) were significantly (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.0001) improved in both the groups, at the end of treatment. There was a significant reduction in mean total composite score (pruritus, erythema, vesicle, and desquamation) after the end of treatment in the sertaconazole group (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.0002) compared to the luliconazole group. Both the groups showed equal negative mycological assessment. Both the study drugs were well tolerated. Only one patient in the sertaconazole group showed allergic contact dermatitis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Sertaconazole was better than luliconazole in relieving signs and symptoms during the study and follow-up period, but cost-effectiveness wise, luliconazole was better than sertaconazole.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/picr.picr_24_19","type":"journal-article","created":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T08:48:17Z","timestamp":1610095697000},"page":"223-228","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Comparison of efficacy, safety, and cost-effectiveness of sertaconazole and luliconazole cream in patients with dermatophytoses"],"prefix":"10.4103","volume":"12","author":[{"given":"Ganesh N.","family":"Dakhale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish V.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayesh I.","family":"Mukhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mrunalini V.","family":"Kalikar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-10-20240829","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2147\/CE.S49629","article-title":"Luliconazole for the treatment of fungal infections: An evidence-based review","volume":"9","author":"Khanna","year":"2014","journal-title":"Core Evid"},{"key":"R2-10-20240829","first-page":"1","article-title":"Comparison of safety and efficacy of luliconazole and other antifungal agents","volume":"5","author":"Chandana","year":"2014","journal-title":"Int J Pharm Sci Res"},{"key":"R3-10-20240829","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4103\/0019-5154.105284","article-title":"Comparative assessment of the efficacy and safety of sertaconazole (2%) cream versus terbinafine cream (1%) versus luliconazole (1%) cream in patients with dermatophytoses: A pilot study","volume":"58","author":"Jerajani","year":"2013","journal-title":"Indian J Dermatol"},{"key":"R4-10-20240829","first-page":"HC09","article-title":"Comparison of topical anti- fungal agents sertaconazole and clotrimazole in the treatment of tinea corporis-an observational study","volume":"8","author":"Shivamurthy","year":"2014","journal-title":"J Clin Diagn Res"},{"key":"R5-10-20240829","doi-asserted-by":"crossref","first-page":"659","DOI":"10.4103\/0253-7613.194850","article-title":"Efficacy and tolerability of topical sertaconazole versus topical terbinafine in localized dermatophytosis: A randomized, observer-blind, parallel group study","volume":"48","author":"Chatterjee","year":"2016","journal-title":"Indian J Pharmacol"},{"key":"R6-10-20240829","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/IDR.S61998","article-title":"A critical appraisal of once-daily topical luliconazole for the treatment of superficial fungal infections","volume":"9","author":"Gupta","year":"2016","journal-title":"Infect Drug Resist"},{"key":"R7-10-20240829","first-page":"792","article-title":"Anti-pruritic effect of sertaconazole 2% Cream in atopic dermatitis subjects: A prospective, randomized, double-blind, vehicle-controlled, multi-centre clinical trial of efficacy, safety and local tolerability","volume":"96","author":"St\u00e4nder","year":"2016","journal-title":"Acta Derm Venereol"},{"key":"R8-10-20240829","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1586\/14787210.2015.1116939","article-title":"Once-daily luliconazole cream 1% for the treatment of interdigital tinea pedis","volume":"13","author":"Gold","year":"2015","journal-title":"Expert Rev Anti Infect Ther"},{"key":"R9-10-20240829","first-page":"s35","article-title":"New topical therapeutic options in the management of superficial fungal infections","volume":"14","author":"Zeichner","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"R10-10-20240829","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1439-0507.2006.01218.x","article-title":"A comparative clinical study between 2 weeks of luliconazole 1% cream treatment and 4 weeks of bifonazole 1% cream treatment for tinea pedis","volume":"49","author":"Watanabe","year":"2006","journal-title":"Mycoses"},{"key":"R11-10-20240829","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2165\/00128071-200708060-00007","article-title":"Comparative study of 2% sertaconazole solution and cream formulations in patients with tinea corporis, tinea pedis interdigitalis, or a corresponding candidosis","volume":"8","author":"Borelli","year":"2007","journal-title":"Am J Clin Dermatol"},{"key":"R12-10-20240829","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1586\/eri.13.17","article-title":"Sertaconazole: an antifungal agent for the topical treatment of superficial candidiasis","volume":"11","author":"Carrillo-Mu\u00f1oz","year":"2013","journal-title":"Expert Rev Anti Infect Ther"},{"key":"R13-10-20240829","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00403-006-0679-8","article-title":"Anti-inflammatory and anti-itch activity of sertaconazole nitrate","volume":"298","author":"Liebel","year":"2006","journal-title":"Arch Dermatol Res"},{"key":"R14-10-20240829","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/j.jacc.2008.09.018","article-title":"Interpreting the results of cost-effectiveness studies","volume":"52","author":"Cohen","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"R17-10-20240829","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/1346-8138.12577","article-title":"Efficacy and tolerability of luliconazole cream 1% for dermatophytoses: A meta-analysis","volume":"41","author":"Feng","year":"2014","journal-title":"J Dermatol"},{"key":"R18-10-20240829","first-page":"32","article-title":"A randomized, multicenter, double-blind, vehicle-controlled study evaluating the efficacy and safety of luliconazole cream 1% once daily for 7 days in patients aged \u226512 years with tinea cruris","volume":"13","author":"Jones","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"R19-10-20240829","doi-asserted-by":"crossref","first-page":"451","DOI":"10.4103\/0019-5154.119955","article-title":"A comparative randomized open label study to evaluate efficacy, safety and cost effectiveness between topical 2% sertaconazole and topical 1% butenafine in tinea infections of skin","volume":"58","author":"Thaker","year":"2013","journal-title":"Indian J Dermatol"}],"container-title":["Perspectives in Clinical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/picr.PICR_24_19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:36:22Z","timestamp":1787844982000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/picr.PICR_24_19"}},"subtitle":["A prospective, randomized, open-label study"],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/picr.picr_24_19","relation":{},"ISSN":["2229-3485"],"issn-type":[{"value":"2229-3485","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]}}}